Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva
| العنوان: | Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva |
|---|---|
| المؤلفون: | Lawrence W. C. Chan, Sze Chuen Cesar Wong, William C. Cho, Wai Ming Stanley Leung, Hin Fung Tsang |
| المصدر: | Expert Review of Molecular Diagnostics article-version (VoR) Version of Record |
| بيانات النشر: | Informa UK Limited, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, COVID-19 diagnosis, Saliva, viruses, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Point-of-care testing, Oropharynx, Real-Time Polymerase Chain Reaction, Sensitivity and Specificity, POCT, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, Nasopharynx, Genetics, Humans, Medicine, Nucleic Acid Amplification Tests, skin and connective tissue diseases, Molecular Biology, Original Research, GeneXpert MTB/RIF, business.industry, fungi, virus diseases, Gold standard (test), SARS-CoV-2 PCR, Virology, body regions, 030104 developmental biology, Real-time polymerase chain reaction, COVID-19 Nucleic Acid Testing, 030220 oncology & carcinogenesis, Performance comparison, Coronavirus disease-2019, Molecular Medicine, business, Research Article, severe acute respiratory syndrome coronavirus 2 |
| الوصف: | Background: Nucleic acid amplification tests (NAATs) based methods such as real-time reverse transcription polymerase-chain reaction (real-time RT-PCR) are the gold standard for diagnosis of current infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The cobas® Liat® and cepheid® GeneXpert® systems are two rapid real-time RT-PCR platforms offering rapid, specimen-to-answer detection of SARS-CoV-2. Research design and methods: In this study, we compared the performance of these two systems on SARS-CoV-2 detection in 9 nasopharyngeal swab (NPS) and 70 posterior oropharyngeal saliva specimens collected from 79 patients suspected of SARS-CoV-2 infection between August 2020 and March 2021. Results: The Positive Percent Agreement (PPA), Negative Percent Agreement (NPA) and overall Percent Agreement (OPA) between cepheid® Xpress SARS-CoV-2 assay and cobas® Liat® SARS-CoV-2 & Influenza A/B assay were found to be 100%. We demonstrated an excellent overall test concordance of the Liat® SARS-CoV-2 & Influenza A/B assay and Xpress SARS-CoV-2 assay. The small sample size of SARS-CoV-2 positive and weak-positive specimens is the inherent limitation of this study. Conclusions: The performance of the cobas® Liat® SARS-CoV-2 & Influenza A/B assay is equivalent to the cepheid® Xpress SARS-CoV-2 assay for SARS-CoV-2 detection using NPS and posterior oropharyngeal saliva. |
| تدمد: | 1744-8352 1473-7159 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84454c5b59de9bc58eb086370da73921 https://doi.org/10.1080/14737159.2021.1919513 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....84454c5b59de9bc58eb086370da73921 |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 17448352 14737159 |
|---|